One Year On Roche’s Herceptin Is Best, Studies Show
This article was originally published in The Pink Sheet Daily
Executive Summary
Two closely watched studies on Herceptin (trastuzumab) suggest neither a shorter nor a longer period of treatment is better at fighting off a recurrence of cancer than the current standard of one year. Roche’s final analysis of HERA and France’s six-month attempt in PHARE were presented Oct. 1 at ESMO.